Did FDA's Green Light for IOV-5001 Basket Trial Just Shift Iovance Biotherapeutics' (IOVA ...

The FDA allowed Iovance Biotherapeutics to proceed with a Phase I/II basket trial of IOV-5001, a next-generation TIL therapy aiming to treat multiple advanced solid tumors with a one-time regimen. This FDA approval modestly strengthens Iovance’s investment narrative by expanding beyond its current key asset Amtagvi, though risks around EMA approvals and manufacturing costs remain.

This Wire brief sits within Fusion42's coverage of Biotech.